- Opinion
- [Reporter's view] PVA market should be actively reflected
- by Lee, Tak-Sun Sep 13, 2022 05:51am
- The pharmaceutical industry is in accordance with PVA didn't like being drug price cut. Excessive government intervention in the law according to the principle of supply and demand markets. Other goods has increased the use of demand than supply shortages, needs to be raised prices. But people pay health insurance run to fund health insurance
- Opinion
- [Reporter’s View] Novartis's restructuring path similar
- by Eo, Yun-Ho Aug 31, 2022 05:40am
- Mergers, split-off, purchases, and sales... Global biopharmaceutical companies are busy making transformations to their respective businesses. Among the various transformations being made, the spin-offs and sales of the multinational pharmaceutical companies’ divisions have received particular attention over the past few years. Although
- Opinion
- [Reporter's view] Reflecting opinions on cold medicine
- by Lee, Hye-Kyung Aug 31, 2022 05:39am
- The Ministry of Food and Drug Safety has been monitoring the supply and demand of cold medicines since March. The targets for monitoring are NSAIDs and Expectorants such as complex cold medicines, Acetaminophen, Ibuprofen, Dexibuprofen, Loxoprofen, and Erdosteine. When pharmaceutical companies computer-report the production (import), sales, a
- Opinion
- [Reporter’s View] Unresolved insulin cold chain issue
- by Aug 24, 2022 05:56am
- With no clear alternative found for insulin distribution in Korea, on how to set the regulations for cold chain transport of insulin remains unresolved and beleaguered. Unlike other biological agents that are mainly prescribed in hospitals, insulin is often dispensed at outside pharmacies. And the lives of patients with Type 1 diabetes, w
- Opinion
- [Reporter's view] Legalization of Non-face-to-face Care
- by Lee, Jeong-Hwan Aug 18, 2022 05:48am
- Non-face-to-face treatment has become a social topic beyond the health and medical community. Non-face-to-face treatment, which has been temporarily allowed since February 2020, has been on the rise for three years, and the public and domestic medical systems, which are users, have naturally become accustomed to non-face-to-face treatment. No
- Opinion
- [Reporter’s View] Industry sullen over revised PE exemption
- by Eo, Yun-Ho Aug 17, 2022 05:52am
- The pharmaceutical industry is sullen despite the government's announcement of a measure to expand drug coverage, as the so-called measures for expanded coverage are closer to reductions from the industry’s point of view. The main issue lies in the improvement of the pharmacoeconomic evaluation (PE) exemption system that was included in
- Opinion
- [Reporter’s View] MFDS opens up, discloses contact info
- by Lee, Hye-Kyung Aug 16, 2022 05:46am
- The Ministry of Food and Drug Safety is changing. The ministry's efforts to transform into an ‘Open MFDS’ as emphasized by Minister Yu-Kyoung Oh since her day of appointment on May 27th, is showing results. After holding 7 ‘ultimate debate’ sessions in June this year, the MFDS also held 16 roundtable meetings and discussion sessions w
- Opinion
- [Reporter’s View] Seek industry opinion before implemention
- by Lee, Tak-Sun Aug 12, 2022 05:58am
- Although the government announced measures to reinforce patient access to high-priced severe disease treatments on the 20th of last month, the pharmaceutical industry’s response to the new measures has been lukewarm at best. Moreover, the industry is ferociously criticizing how the government presented the measure without collecting industr
- Opinion
- [Reporter's view] COVID-19 vaccination strategy
- by Aug 9, 2022 05:56am
- The MFDS has begun a preliminary review of the vaccine for COVID-19 in Moderna and Pfizer. The preliminary review is to review the submitted clinical data in advance and to quickly determine whether to grant permission when the company applies for an item permit by adding non-clinical and quality data in the future. The divalent vaccine, w
- Opinion
- [Reporter’s View] New guideline refrains off-label NOAC use
- by Eo, Yun-Ho Aug 2, 2022 06:02am
- Off-label refers to the use of drugs for an indication other than those approved by the Ministry of Food and Drug Safety. Although people may question the need for off-label use when the appropriate use for a drug has already been set by the health authorities, these off-label prescriptions are made at the doctor’s discretion. Often,
